간경변 치료 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 치료 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Liver Cirrhosis Treatment Market size was valued at USD 18.9 Billion in 2024 and is poised to grow from USD 20.11 Billion in 2025 to USD 33.03 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The global liver cirrhosis treatment market is responding to increasing challenges posed by liver disease, driven by lifestyle changes, rising alcohol consumption, and poor dietary habits. The prevalence of chronic liver disease, which affects approximately 1.5 billion individuals worldwide, highlights the growing urgency for innovative therapeutic solutions. Hepatitis B remains a significant contributor to liver cirrhosis and hepatocellular carcinoma, with alarming mortality rates linked to the disease. Key trends influencing market growth include the increasing global incidence of liver conditions, particularly non-alcoholic fatty liver disease (NAFLD), which is expected to surge considerably. With major pharmaceutical companies investing heavily in research to develop new treatments, the market is poised for expansion as awareness and diagnosis of liver diseases continue to improve globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cirrhosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cirrhosis Treatment Market Segments Analysis

Global Liver Cirrhosis Treatment Market is segmented by Disease Type, Treatment Type, End User and region. Based on Disease Type, the market is segmented into Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis and Cryptogenic Cirrhosis. Based on Treatment Type, the market is segmented into Immunosuppressants, Antibiotics, Vaccines, Anti-viral drugs and Corticosteroids. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cirrhosis Treatment Market

The prevalence of liver disease continues to be a significant global concern, primarily due to factors such as sedentary lifestyles, inadequate physical activity, and poor dietary habits. This, combined with an aging population and the rise of autoimmune conditions like hepatitis and non-alcoholic fatty liver disease, has led to a growing number of patients requiring treatment. Furthermore, increasing alcohol consumption has contributed to the higher incidence of liver-related ailments. The market for liver disease treatments is expected to flourish as healthcare organizations respond to the demand for therapies, driving innovation in drug and device development through partnerships with biotechnology and research firms. This competitive landscape is set to create numerous opportunities for stakeholders, thereby fueling market expansion.

Restraints in the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market faces several significant challenges that impede its growth. The high costs associated with medications, procedures, and surgeries necessary for effective liver disease management are primary factors hindering market development. Limited healthcare access, particularly in rural and underserved regions, contributes to this issue, compounded by a general lack of awareness around liver diseases and their symptoms among both the public and healthcare providers. Additionally, the stigma surrounding certain liver conditions, such as those linked to alcohol or bacterial infections, further complicates matters. Furthermore, the difficulties associated with liver transplantation, strict regulatory requirements, and a shortage of innovative drugs in the research and development pipeline also restrict market advancement. The substantial financial burden required for treatment adds to the overarching market restraints.

Market Trends of the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market is witnessing significant growth driven by a surge in research and development aimed at new therapeutic solutions and improved diagnostic techniques. Factors such as heightened awareness of liver diseases, preventive services, and funding for treatment underscore the urgency for early diagnosis and management of these conditions. Additionally, demographic shifts with an aging population, improved healthcare infrastructure, and rising disposable incomes in emerging markets contribute to market expansion. Advancements in surgical procedures and non-invasive radiology interventions further enhance treatment options, collectively fostering a robust environment for innovative liver disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Liver Cirrhosis Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Alcoholic Cirrhosis
• Atrophic Cirrhosis
• Biliary Cirrhosis
• Cryptogenic Cirrhosis

Global Liver Cirrhosis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Immunosuppressants
• Antibiotics
• Vaccines
• Anti-viral drugs
• Corticosteroids

Global Liver Cirrhosis Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Other

Global Liver Cirrhosis Treatment Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galectin Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akero Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poxel SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations